Testing a new inhaled powder to help people breathe better with COPD

Plain-English translation of NCT07583849 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a medication called HSK39004, which comes as an inhaled powder, to see if it can help people with COPD (a serious lung disease that makes breathing difficult). Researchers will compare this new treatment to a placebo (a dummy inhaler with no active medication) over 12 weeks to measure whether the medication improves lung function and reduces breathing problems.

COPD is a chronic disease that gets worse over time and limits how much people can do in daily life. This study exists to see whether this medication can offer a new treatment option to help people with COPD breathe easier and feel better.

Do you qualify?

You likely qualify if…

you are between 40 and 80 years old
you have been diagnosed with COPD for at least one year and have symptoms like shortness of breath or chronic cough
your lung function tests show a specific pattern of airway narrowing that matches COPD
you have a smoking history (either current smoker or former smoker with significant pack-years) or exposure to other lung irritants
your breathing difficulty is at least moderate in severity, as measured by a standard scale

You likely don't qualify if…

you have had a COPD flare-up requiring hospitalization or acute treatment within the past 12 weeks
you have had a recent lung infection (within 6 weeks) that required antibiotics
you have been diagnosed with other serious lung diseases besides COPD, such as asthma, tuberculosis, cystic fibrosis, or pulmonary fibrosis
you have serious heart problems, including recent heart attacks, severe heart failure, or severe irregular heartbeats
you have a known allergy to lactose, milk protein, or any of the ingredients in this inhaled medication

What participation looks like

You would visit the research clinic for a screening appointment where they check your lung function and medical history. If you qualify, you would be randomly assigned to either receive the new inhaled medication or a placebo, and use it twice daily for 12 weeks. You would return for follow-up visits so the research team can monitor how you're doing, measure your lung function again, and watch for any side effects.

AI-generated summary from trial data · Jun 17, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University People's Hospital, Beijing, Beijing Municipality